Pulmonary arterial hypertension

American Journal of the Medical Sciences

Volumn 335, Issue 1, 2008, Pages 40-45

  Highland, Kristin B ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b 812 CSB ^*  (United States)

Author keywords

Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; ARGININE; BERAPROST; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CARDIAC GLYCOSIDE; DIGOXIN; DIPYRIDAMOLE; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; DRUG INHIBITION; DRUG MECHANISM; ELECTROCARDIOGRAM; FUNCTIONAL ASSESSMENT; HEART CATHETERIZATION; HUMAN; LUNG FUNCTION TEST; MORBIDITY; OXIMETRY; PATIENT CARE; POLYSOMNOGRAPHY; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SURVIVAL RATE; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

EID: 38349006730     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31815d2647     Document Type: Review

References (25)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
2. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:7S-10S.
3. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
4. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
5. Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64.
6. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987;107:216-23.
7. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP Evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
8. Galiè N, Manes A, Farahani KV, et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005;14:713-17.
9. Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health are level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32.
10. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007;28:203-18.
11. Mesa RA, Edell ES, Dunn WF, et al. Human immunodeficiency virus infection and pulmonary hypertension: Two new cases and a review of 86 reported cases. Mayo Clin Proc 1998;73:37-45.
12. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-95.
13. Atwood CW, McCrory D, Garcia JG, et al. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence based clinical practice guidelines. Chest 2004;126:72S-7S.
14. Nocturnal Oxygen Treatment Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Ann Intern Med 1983:93; 391-8.
15. King MA, Ysrael M, Bergin CJ. Chronic thromboembolic pulmonary hypertension: CT findings. AJR Am J Roentgenol 1998;170:955-60.
16. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S-92S.
17. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-40.
18. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest 2004;126:35S-62S.
19. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2002;102:865-70.
20. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-92.
21. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
22. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580-7.
23. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28.
24. Hoeper MM, Markevvch I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2004;26:858-63.
25. Hyduk A, Croft JB, Ayala C, et al. Pulmonary hypertension surveillance: United States, 1980-2002. MMWR 2005;54:SS-5.